Strong Growth is Expected in the CMO Biopharmaceuticals’ Market
The global ostomy market, valued at $1.7 billion in 2007 grew at a CAGR of 5.6 percent in last five years.
A new report from IMARC Group finds that one of the biggest advantages of biopharmaceuticals over conventional small molecule drugs is their high efficacy and target oriented nature.
A new report from IMARC Group expects the strong growth of biopharmaceuticals and the launch of biosimilars to create huge opportunities for cold chain service providers
With outsourcing trends in the global clinical trials market increasing rapidly, the demand of efficient cold chain logistic services is predicted to grow robustly in the coming years.
Strong Growth is expected in the Overall Upstream Process market
Page 1 of 1